Scarica l'app Stockscreener
1.62
2.53%
0.04
Pre-mercato:
1.60
-0.02
-1.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo! Finance Canada
Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History - Yahoo! Finance Canada
How to build the scientific case that gets your grant funded - PacBio
PACB Stock Firms Up Ahead Of Morgan Stanley Healthcare Chat - StocksToTrade
Pacific Biosciences of California (PACB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push - Yahoo Finance
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating - Moomoo
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
How to build a more competitive grant proposal without losing your research time to it - PacBio
Pacific Biosciences Coverage Assumed by UBS at Neutral - Moomoo
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks - The Globe and Mail
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? - Eastern Progress
PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference - marketscreener.com
PACB stock gains as PacBio highlights sequencing strength ahead Morgan Stanley conference - ad-hoc-news.de
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference - marketscreener.com
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - TradingView
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test - TradingView
3 Reasons to Sell PACB and 1 Stock to Buy Instead - Yahoo Finance
Pacific Biosciences (PACB) Tumbles 9.7% to $1.40, Nears Critical Support at $1.33Stock News - vinanet.vn
PACB Q2 2026 Earnings: Wider-than-Expected Per-Share Loss Drives 9.68% SelloffEstimate Uncertainty - careplusvn.com
Pacific (PACB) EPS and Revenue: EPS Misses Its Estimate in the Reported Period; Share Response: The Stock Loses 5.19% on the DayEarnings Preview - careplusvn.com
Pacific (PACB) Momentum: Ends Higher by 9.76% at $1.35 for the Current Session; Price Levels - careplusvn.com
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Pacific (PACB) Earnings Update: EPS Misses Its Estimate on the Day; Trading Response: Shares Close 11.40% Higher in Latest TradingEarnings Weakness Phase - Vinanet
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - Stock Titan
Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus
Pacific Biosciences of California Inc (PACB) (Q2 2026) Earnings - GuruFocus
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing (Aug 17, 2026) - Stock Titan
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - MarketBeat
ARK reports 9.59% stake in Pacific Biosciences (PACB) - Stock Titan
5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call - Yahoo Finance
PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs - Stock Titan
Measuring – not guessing – the true path - PacBio
Weekly Recap: PACB cuts 2026 revenue guide and Mark Van Oene named CEO - TradingView
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC - MarketBeat
Pacific Biosciences of California, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-08-08 - Seeking Alpha
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29 - simplywall.st
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen - MarketBeat
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary - TradingView
Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside - TradingView
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3 - Moomoo
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut - Yahoo Finance
Pacific Biosciences (PACB) Drops 6.5% to $1.22, Testing Key Support LevelSmart Money Flow Stocks - careplusvn.com
Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Q2 Earnings Call Highlights - TradingView
Pacific Biosciences of California, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce - Moomoo
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
1.51%
0.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):